| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Certara delivers a solid quarter with double-digit software revenue growth |
| 07 Aug 2026 |
8-K: Regulation FD Disclosure
On August 4, 2026, Certara, Inc. (the “Company”) hosted its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation. On the earnings conference call, there was a misstatement i... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program |
| 04 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’s President, Chief Commercial Officer, effective as of August 1, 2026. The Company intends to retain Mr. Pedersen a... |
| 17 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
RADNOR, PA – June 17, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effe... |
| 15 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, Certara, Inc. (the “Company”) held its annual meeting of stockholders. The proposals are described in the Company’s proxy statement for the 2026 Annual Meeting of Stockholders filed with the Securities and Exchange Commi... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business |
| 22 Apr 2026 |
8-K: Entry into a Material Definitive Agreement
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence |
| 31 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) |
| 11 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
RADNOR, PA— November 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. |
| 16 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
SIXTH AMENDMENT, dated as of October 16, 2025 (this “Agreement”), to the Credit Agreement dated as of August 15, 2017 (as amended by the First Amendment thereto, dated as of January 24, 2018, by the Second Amendment thereto, dated as of ... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. |
| 22 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2025, Certara, Inc. (the “Company”) held its annual meeting of stockholders. The proposals are described in the Company’s proxy statement for the 2025 Annual Meeting of Stockholders filed with the Securities and Exchange Commi... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
RADNOR, PA— May 5, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. |
| 14 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
RADNOR, PA — April 14, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter ... |
| 05 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advi... |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
RADNOR, PA - February 26, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. |
| 15 Jan 2025 |
8-K: Results of Operations and Financial Condition
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million |
Loading...